Critical Analysis: 60 Degrees Pharmaceuticals (NASDAQ:SXTP) vs. Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, profitability and dividends.

Risk & Volatility

Eli Lilly and Company has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.54, suggesting that its stock price is 154% more volatile than the S&P 500.

Profitability

This table compares Eli Lilly and Company and 60 Degrees Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	33.53%	97.83%	23.23%
60 Degrees Pharmaceuticals	-650.21%	N/A	-136.81%

Earnings & Valuation

This table compares Eli Lilly and Company and 60 Degrees Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$65.18 billion	16.11	$20.64 billion	$29.80	37.43
60 Degrees Pharmaceuticals	$1.41 million	2.25	-$7.36 million	($4.82)	-0.19

Eli Lilly and Company has higher revenue and earnings than 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Eli Lilly and Company and 60 Degrees Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	1	4	24	1	2.83
60 Degrees Pharmaceuticals	1	2	1	0	2.00

Eli Lilly and Company presently has a consensus target price of $1,295.39, indicating a potential upside of 16.12%. 60 Degrees Pharmaceuticals has a consensus target price of $13.85, indicating a potential upside of 1,438.89%. Given 60 Degrees Pharmaceuticals’ higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Eli Lilly and Company.

Summary

Eli Lilly and Company beats 60 Degrees Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.